Depo-Provera brain tumor lawsuits

• Meningioma. Plaintiffs allege that recent scientific studies show long-term use of Depo-Provera can increase the risk of developing one or more meningiomas, tumors that grow from the membranes around the brain and spinal cord. The MDL is limited to people who allege an intracranial meningioma caused by Depo-Provera or a generic version.
• Warnings. The lawsuits allege the makers knew or should have known of the risk and failed to adequately warn patients and doctors.
• Safer alternative. Plaintiffs also allege the makers failed to promote Depo-SubQ Provera 104, which plaintiffs contend is safer because it uses a lower dose given under the skin.

Our attorneys look at

• When you received injections and for how long
• Whether you received brand-name Depo-Provera or a generic version
• When and how your meningioma was diagnosed, and the treatment you needed, such as monitoring, surgery or radiation

You don't need everything on this list to ask for an evaluation. Gather what you can.

• Records of your injections: clinic, doctor's office or pharmacy records with dates
• The names of the providers who gave the injections
• The MRI or CT report that found the meningioma, and the date of diagnosis
• Records from your neurologist or neurosurgeon, including any surgery or pathology report
• Records of radiation or other treatment
• A short timeline of your symptoms, such as headaches, vision changes or seizures
• Records of missed work or other effects on your daily life

• LitigationMDL No. 3140
• CourtU.S. District Court for the Northern District of Florida (Pensacola Division)
• JudgeJudge M. Casey Rodgers
• CreatedFebruary 7, 2025

As of October 2026, lawsuits allege that long-term use of Depo-Provera, or a generic version, can increase the risk of meningioma and that the makers failed to adequately warn about that risk. The MDL is pending before Judge M. Casey Rodgers in the Northern District of Florida.

In a June 15, 2026 order, the court noted an agreement between plaintiffs' leadership counsel and the Pfizer defendants under which plaintiffs who meet eligibility criteria agreed by those parties will have an opportunity to resolve their claims. The court said that agreement, once finalized, will not resolve every case in the MDL, and it continued proceedings on the parties' expert evidence. The court lists a case management conference for December 18, 2026.

What regulators have said

The FDA-approved prescribing information for Depo-Provera CI was revised in December 2025 to add a Warnings and Precautions section on meningioma.

Status checked October 12, 2026. This MDL is listed as pending on the JPML report of pending MDLs dated October 1, 2026 (opens in a new tab). Court dockets change; each page shows the date it was last checked.

More questions in the FAQ

• U.S. District Court, Northern District of FloridaU.S. District Court, N.D. Fla.: Depo-Provera Products Liability Litigation, MDL No. 3140flnd.uscourts.gov (opens in a new tab)
• Judicial Panel on Multidistrict LitigationJPML Transfer Order, MDL No. 3140 (filed Feb. 7, 2025)jpml.uscourts.gov (opens in a new tab)
• U.S. District Court, Northern District of FloridaN.D. Fla.: Pretrial Order No. 30A (filed June 15, 2026)flnd.uscourts.gov (opens in a new tab)
• National Library of Medicine, DailyMedDailyMed: Depo-Provera CI prescribing informationdailymed.nlm.nih.gov (opens in a new tab)
• U.S. Food and Drug AdministrationFDA: Depo-Provera CI label, revised December 2025accessdata.fda.gov (opens in a new tab)